• Теги
    • избранные теги
    • Компании2331
      • Показать ещё
      • Показать ещё
      Страны / Регионы315
      • Показать ещё
      Международные организации54
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
19 июля, 17:15

Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

14 июля, 01:11

Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

13 июля, 15:39

T-cell cancer therapy holds promise, longer-term results await

A novel cell treatment that saved the life of 9-year-old Austin Schuetz was given the green light by US regulatory advisers on Wednesday and doctors hope it can save the lives of more children with the

11 июля, 23:44

Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

Выбор редакции
11 июля, 21:21

The Game Changes: Is Bristol-Myers Squibb The End Of An Era?

A recent Supreme Court decision tilts the odds in favor of corporate defendants but companies should not underestimate how resourcefully the plaintiffs’ bar will seek to recover.

07 июля, 16:16

Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

07 июля, 15:25

Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

06 июля, 21:22

Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study

Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis.

06 июля, 17:52

Company News for July 06, 2017

Companies in the News are: ORLY,BMY,MORE,PRPO

30 июня, 15:15

Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

29 июня, 22:53

M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

Выбор редакции
27 июня, 18:22

A Closer Look At Bristol-Myers Squibb's Oncology Business

Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Empirically and fundamentally speaking, the stock’s performance is highly tied to clinical trial results and the uptake of the company’s new cancer drugs.

27 июня, 17:03

Gilead's (GILD) HCV Drug Application Accepted in the EU

Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

Выбор редакции
27 июня, 17:01

Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

27 июня, 17:01

Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

27 июня, 16:26

AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

23 июня, 14:42

Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

22 июня, 00:18

U.S. Supreme Court Ruling Threatens Massive Talc Litigation Against J&J

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer. New Jersey-based J&J has been battling a series of lawsuits over its talc-based products, including Johnson’s Baby Powder, brought by around 5,950 women and their families. The company denies any link between talc and cancer. A fifth of the plaintiffs have cases pending in state court in St. Louis, where juries in four trials have hit J&J and a talc supplier with $307 million in verdicts. Those four cases and most of the others on the St. Louis docket involve out-of-state plaintiffs suing an out-of-state company. On Monday, the Supreme Court ruled 8-1 in a case involving Bristol-Myers Squibb Co that state courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there. The ruling immediately led a St. Louis judge at J&J’s urging to declare a mistrial in the latest talc case, in which two of the three women at issue were from out of state. It also could imperil prior verdicts and cases that have yet to go to trial. “We believe the recent U.S. Supreme Court ruling on the Bristol-Myers Squibb matter requires reversal of the talc cases that are currently under appeal in St. Louis,” J&J said in a statement. The question of where such lawsuits can be filed has been the subject of fierce debate. The business community has argued plaintiffs should not be allowed to shop around for the most favorable court to bring lawsuits, while injured parties claim corporations are trying to deny them access to justice. Along with talc cases, large-scale litigation alleging injuries from Bayer AG’s Essure birth control device in Missouri and California and GlaxoSmithKline’s antidepressant Paxil in California and Illinois are examples of other cases where defendants could utilize the Supreme Court decision. Although he declared a mistrial on Monday, St. Louis Circuit Judge Rex Burlison left the door open for the plaintiffs to argue they still have jurisdiction. Plaintiffs lawyer Ted Meadows said he would argue the St. Louis court still had jurisdiction based on a Missouri-based bottler J&J used to package its talc products, which he said would create a sufficient connection to the state. “It’s very disappointing to mistry a case because the Supreme Court changed the rules on us,” said Meadows. The lawsuit decided by the high court on Monday involved claims against Bristol-Myers and California-based drug distributor McKesson Corp by 86 California residents and 575 non-Californians over the blood thinner Plavix. Beyond Monday’s mistrial, the Supreme Court’s ruling could bolster a pending appeal by J&J of a $72 million verdict in favor of the family of Alabama resident Jacqueline Fox, who died in 2015. A Missouri appeals court had said in May it would wait until the Supreme Court issued its decision to decide the appeal. J&J has won only one of the five trials so far in Missouri. It previously sought to move talc cases out of St. Louis, but the Missouri Supreme Court in January denied its bid. The company has also cast the St. Louis court as overly plaintiff-friendly and has allowed evidence linking talc to cancer that was rejected by a New Jersey state court judge overseeing over 200 talc cases. The plaintiffs are appealing. The talc verdicts against J&J led the business-friendly American Tort Reform Association last year to declare the St. Louis state court the nation’s top “Judicial Hellhole.” Now J&J could try to use the Supreme Court ruling to dismiss many of the cases it faces in Missouri, according to legal experts. Corporations facing a large volume of cases in venues chosen by plaintiffs will likely cite the Supreme Court to try to dismiss those claims, said Rusty Perdew, a defense lawyer at the law firm Locke Lord. “You have a bunch of defendants who can go back and say, ‘Judge, you got that wrong and you’re going to have to dismiss claims by all those plaintiffs,’” he said. (This story was corrected to show that Perdew was speaking about corporations in general, not J&J, in next-to-last paragraph.)   (Reporting by Nate Raymond in Boston; Editing by Tom Brown and Bill Trott) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

21 июня, 17:57

AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

21 июня, 00:35

Exelixis's Cabometyx Positive for First-Line Kidney Cancer

Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

04 августа 2015, 19:21

Глобальная мировая бизнес-сеть

Хотя точнее её было бы назвать не мировой, а всё же американской. Потому что мировая она по охвату, но по центру владения собственностью и принятия решений она - американская. Эту инфографику опубликовали в июне этого года на сайте InfoWeTrust.com на основании статистики Bloombergresearch. Она отражает связи руководящего состава крупнейших международных компаний. Члены советов директоров одновременно занимают директорские должности в нескольких компаниях, что, как понимаете, конфликтует с заявляемой «свободой конкуренции»: если «рука рынка» в лице конкретного директора руководит конкурентами, то это какая-то странная конкуренция, как думаете? Впрочем, это не новость: в 2002 году газеты USA Today и The Financial Times проводили исследование связей между членами советов директоров крупнейших корпораций мира на основе аналитической базы The Corporate Library. Выяснилось, что в ведущих 500 компаниях мира каждый седьмой директор входит в совет директоров другой корпорации. В «личном первенстве» лидировал президент немецкой страховой компании «Allianz» Хеннинг Шульте-Нелле, который в 2002 году заседал в советах директоров разных компаний со 184 руководителями крупнейших компаний мира. USA Today выяснили, что в 11 из 15 крупнейших компаний США двое и более директоров входят в совет директоров другой компании. Ситуацию образно описал профессор Мичиганского университета Джеральд Дэвис: «Если бы член совета директоров JP Morgan Chase подхватил вдруг заразную болезнь, в течение шести месяцев заразились бы 97% директоров крупных компаний». Этот феномен даже имеет свое название — «interlocking directorate» (совмещенный директорат), что указывает на устойчивость явления. Формально, по законам США, такое запрещено для конкурирующих компаний, но конкуренция-то не всегда прямая, да и важна сама возможность общения. Например, компании «PepsiCo» и «Coca-Cola» – традиционные конкуренты и не участвуют в управлении друг другом, однако члены совета директоров «PepsiCo» Роберт Аллен и Джеймс Робинсон («Coca-Cola») вместе заседают в совете директоров фармацевтической компании «Bristol-Myers Squibb». Нетрудно догадаться, что ведущую роль в такой «кооперации» играют крупные финансовые фонды и банки. Либеральные мантры о «свободе конкуренции» лишь служат идеологическим прикрытием централизации капитала. Так, крупных брендов в мире значительно больше, чем их владельцев — компании стремятся перекрыть рынок разными марками товаров от одного владельца, а не допускать каких-то там конкурентов к дележу «пирога».